Tvardi Therapeutics, Inc. Common Stock (TVRD) is a publicly traded Healthcare sector company. As of July 7, 2026, TVRD trades at $3.47 with a market cap of $18.95M and a P/E ratio of -0.81. TVRD moved +46.77% today. Year to date, TVRD is -52.48%; over the trailing twelve months it is -91.05%. Its 52-week range spans $1.50 to $43.65. Analyst consensus is buy with an average price target of $9.80. Rallies surfaces TVRD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tvardi TTI-109 Prodrug Delivers 60% STAT3 Cell Reduction, 0.46-Day Diarrhea: Tvardi’s Phase 1 study showed TTI-109 converted to TTI-101 within two hours, achieving dose-proportional pharmacokinetics with plasma levels above the STAT3 IC₅₀. The prodrug demonstrated up to 60% reductions in STAT3-driven Th17, Tfh and B cells and cut diarrhea duration to 0.46 days versus 3.35 days.
| Metric | Value |
|---|---|
| Price | $3.47 |
| Market Cap | $18.95M |
| P/E Ratio | -0.81 |
| EPS | $-2.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.65 |
| 52-Week Low | $1.50 |
| Volume | 23.68M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-18.21M |
| Gross Margin | 0.00% |
6 analysts cover TVRD: 0 strong buy, 4 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.80.